Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lan Lin

Showing results (691-700 of 696) with videos related to

Pageof 70
Sort By:
You have reached the last page of results.This site can display upto 696 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II TrialHai-Dong Zhu, Wei-Jun Fan, Chang Zhao, et al.
Cell Death Discovery|August 29, 2021
Exosomal microRNA-15a from mesenchymal stem cells impedes hepatocellular carcinoma progression via downregulation of SALL4Yu-Shui Ma, Ji-Bin Liu, Lan Lin, et al.
Hepatology International|October 21, 2023
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendationsMing Zhao, Zhi Guo, Ying-Hua Zou, et al.
JCO Precision Oncology|November 7, 2024
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic SignificanceKathleen Conway, Sharon N Edmiston, Amanda Vondras, et al.
Eclinicalmedicine|May 15, 2024
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation studyZhi-Cheng Jin, Jian-Jian Chen, Xiao-Li Zhu, et al.
Signal Transduction and Targeted Therapy|February 8, 2023
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)Hai-Dong Zhu, Hai-Liang Li, Ming-Sheng Huang, et al.
Pageof 70

Showing results (691-700 of 696) with videos related to

Sort By:
Pageof 70
You have reached the last page of results.This site can display upto 696 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II TrialHai-Dong Zhu, Wei-Jun Fan, Chang Zhao, et al.
Cell Death Discovery|August 29, 2021
Exosomal microRNA-15a from mesenchymal stem cells impedes hepatocellular carcinoma progression via downregulation of SALL4Yu-Shui Ma, Ji-Bin Liu, Lan Lin, et al.
Hepatology International|October 21, 2023
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendationsMing Zhao, Zhi Guo, Ying-Hua Zou, et al.
JCO Precision Oncology|November 7, 2024
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic SignificanceKathleen Conway, Sharon N Edmiston, Amanda Vondras, et al.
Eclinicalmedicine|May 15, 2024
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation studyZhi-Cheng Jin, Jian-Jian Chen, Xiao-Li Zhu, et al.
Signal Transduction and Targeted Therapy|February 8, 2023
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)Hai-Dong Zhu, Hai-Liang Li, Ming-Sheng Huang, et al.
Pageof 70